ASCO 2022 | Second-line treatment strategies for pancreatic cancer

Alfredo Carrato, MD, PhD, Hospital Ramón y Cajal, Madrid, Spain, gives an overview of treatment options for patients who progress on first-line treatments for pancreatic cancer including taxane-based chemotherapy and gemcitabine. Oxaliplatin and 5-fluorouracil as part of FOLFOX as well as liposomal irinotecan (nal-IRI) are typically administered when patients progress from the current first-line treatments. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.